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In The Lancet, Séverine Vermeire and colleagues1 report 
the results of a double-blind, randomised, placebo-
controlled phase 2 trial that studied the eﬀ ects of 
etrolizumab—a humanised monoclonal antibody that 
selectively binds the β7 subunit of both the α4β7 and 
αEβ7 integrins—on the induction of remission in patients 
with moderate-to-severe ulcerative colitis. 124 patients 
were randomised, and clinical remission at week 10 (the 
primary endpoint) was achieved in a signiﬁ cantly higher 
proportion of patients in the etrolizumab groups than 
in the placebo group (eight patients of 39 analysed in 
the etrolizumab 100 mg group [21%, 95% CI 7–36], 
four of 39 in the etrolizumab 300 mg plus loading dose 
group [10%, 0·2–24], and none of 41 patients in the 
placebo group). As in the phase 1 study,2 the treatment 
was well tolerated. Considering these results, and the fact 
that the population of patients included in the trial was 
particularly refractory to other powerful treatments, such 
as anti-TNFα and immunosuppressants, etrolizumab has 
great potential to become a new therapeutic option for 
patients with ulcerative colitis.
Several other ﬁ ndings and features of this study 
contribute to make it a milestone in trials of ulcerative 
colitis treatment. First, the proportion of patients with 
clinical remission at week 10 in the placebo group was nil. 
In other trials focused on moderate-to-severe ulcerative 
colitis therapies,3–6 similar results have never been reported, 
and remission in the placebo group has always ranged 
between 5·4% and 14·9%. One of the main possible 
explanations of Vermeire and colleagues’ observation 
is the use of central reading for endoscopic scores. This 
rigorous approach had never been implemented in studies 
of biological therapies in ulcerative colitis before, but 
has been shown to be fundamental for both the correct 
enrolment of patients and the results of multicentre 
clinical trials in this disease.7 The level of concordance 
between local and central endoscopic scoring used by 
Vermeire and colleagues1 might conﬁ rm this hypothesis. 
Furthermore, since the rate of remission was 5% in the 
placebo group at week 6, the choice of an appropriate 
timepoint for the assessment of the primary outcome (10 
weeks) might have also contributed to the results.
Another key feature of Vermeire and colleagues’ 
study1 concerns the pharmacodynamics of etrolizumab, 
including the analysis of β7 occupancy and expression on 
T-lymphocyte and B-lymphocyte subsets in peripheral 
blood and colonic tissue, quantiﬁ cation of αE+ cells, and 
gene expression of cytokines and adhesion molecules. The 
advantage that etrolizumab has over other anti-adhesion 
therapies is its potential to interfere with the αEβ7/E-
cadherin pathway and thereby reduce intraepithelial 
leucocytes in the gut.8 The immunohistochemistry 
analysis of colonic biopsies in Vermeire and colleagues’ 
study showed an apparent decrease in the proportion of 
αE+ cells in the intestinal crypt epithelium of patients in 
the etrolizumab groups, especially in those who achieved 
clinical remission. The absence of statistical signiﬁ cance 
for this endpoint might have been because the timepoint 
for histological examination was too short, assuming 
that changes in tissue take longer to appear than do other 
outcomes. A higher number of αE+ cells at baseline seems 
to be related to clinical remission, representing a possible 
predictive factor of response to etrolizumab.
Patients assigned to higher doses of the active drug 
(etrolizumab 300 mg plus loading dose) paradoxically 
had less clinical beneﬁ t than did those assigned to 100 mg 
etrolizumab.1 The investigators discuss their ﬁ ndings in 
detail, postulating that etrolizumab might also interfere 
with the migration of other cell types, such as regulatory T 
cells. Although the possible link between regulatory T cells 
and α4β7 integrins has already been shown in mice,9 the 
mechanisms underlying these results should be further 
investigated in human beings. The investigators indirectly 
compare eﬃ  cacy outcomes between etrolizumab and 
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New era for treatment in diﬀ erentiated thyroid cancer
Multikinase inhibitors were introduced into clinical 
trials for radioactive iodine-refractory diﬀ erentiated 
thyroid cancer a decade ago. In The Lancet, Marcia Brose 
and colleagues1 report the results of DECISION, the ﬁ rst 
phase 3 randomised, double-blind, placebo-controlled 
clinical trial with the multikinase inhibitor sorafenib 
in diﬀ erentiated thyroid cancer. On the basis of this 
landmark trial, sorafenib received an orphan designation 
by the European Medicine Agency in diﬀ erentiated thyroid 
cancer,2 and was approved by the US Food and Drug 
Administration (FDA) for treatment of radioactive iodine-
refractory diﬀ erentiated thyroid cancer in November, 
2013.3 Sorafenib is only the fourth drug to be approved by 
the FDA for treatment of thyroid cancer. Several decades 
after doxorubicin was introduced for this indication 
in 1974,4 vandetanib (2011) and cabozantinib (2012) were 
approved for medullary thyroid cancer. It is now an exciting 
time for the specialty as strong collaborative research 
initiated by academia, industry, and governmental 
agencies has revolutionised treatment for thyroid cancer.
Thyroid cancer has one of the fastest growing 
incidences of any cancer in high-income countries.5 
Diﬀ erentiated thyroid cancer accounts for about 90% of 
all thyroid cancers and includes papillary, follicular, poorly 
diﬀ erentiated, and Hürthle cell histologies. Although 
the disease generally has a good prognosis, patients 
who develop metastatic radioactive iodine-refractory 
diﬀ erentiated thyroid cancer have an overall survival 
of only 10–20% at 10 years.6 Cytotoxic chemotherapy 
including doxorubicin has yielded disappointing results.4 
In 2003, discovery of oncogenic BRAF mutations 
in papillary thyroid cancer,7 with a frequency of 
approximately 45%, opened a new pathway for drug 
development. Sorafenib, a serine-threonine kinase 
inhibitor, designed to target BRAF and subsequently 
found to have several targets including RET and vascular 
endothelial growth factor receptor, was being tested at 
the time in early-phase clinical trials for various cancers.
For our phase 2 clinical trial,8 the preliminary results 
showing anticancer activity of sorafenib in diﬀ erentiated 
thyroid cancer were presented in August, 2005 and were 
received enthusiastically. Three additional prospective 
phase 2 trials of sorafenib showed encouraging eﬃ  cacy 
in diﬀ erentiated thyroid cancer (table).8–12 Furthermore, 
several other multikinase inhibitors that target 
angiogenesis—eg, sunitinib, pazopanib, and lenvatinib—
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vedolizumab.1 However, the vedolizumab phase 2 study10 
included diﬀ erent populations of patients with ulcerative 
colitis, and had diﬀ erent deﬁ nitions of endpoints and 
timepoint assessments, so any comparison between 
these trials is premature and potentially unreliable.
In conclusion, the results of the present study conﬁ rm 
that anti-integrin therapies might be a valid option for 
the medical management of patients with moderate-to-
severe ulcerative colitis, and support further studies (eg, 
NCT01461317 and NCT02100696) to validate clinical 
eﬃ  cacy and long-term safety of etrolizumab in this 
group of patients with diﬃ  cult-to-treat ulcerative colitis.
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